Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for screening ongoing progress of alzheimer's disease by using beta amyloid oligomer in nasal discharge specimen and method for screening ongoing progress of alzheimer's disease by using same

a technology of beta amyloid and alzheimer's disease, which is applied in the direction of material analysis, biological material analysis, instruments, etc., can solve the problems of high patient cost, time-consuming and costly methods, and abnormal increase or decrease of electrical activity of the brain nerve, so as to screen accurately and quickly, easily and accurately screen alzheimer's onset and stage of development, and save patient cost

Pending Publication Date: 2021-01-14
DAEGU GYEONGBUK INST OF SCI & TECH +1
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides a method for accurately and quickly screening the progress of Alzheimer's disease by identifying two beta amyloid oligomers in a nose discharge sample. This non-invasive method can screen Alzheimer's onset and stage of development easily and accurately without complicated pretreatment of sample, and is economical in cost. This method can greatly assist in establishing a patient-oriented and effective strategy for treating Alzheimer's disease.

Problems solved by technology

As a cause unknown to date, a specific group of brain cells gradually lose their functions in the brain, it is known to be caused by death of brain nerve cells which are the most important for the communication of the brain nervous system, problems in the formation or function of synapses that transfer information between brain cells and brain cells, or an abnormal increase or decrease in the electrical activity of the brain nerve.
To date, Alzheimer's disease can be diagnosed by only neuropsychological tests such as Short Form of Geriatric Depression Scale (GDS) or mini-mental state examination (MMSE), or specialized MRI imaging, which are time-consuming and costly methods.
However, such an image-based diagnostic method not only requires a high cost to the patient, but also detects disease in a state where brain contraction or damage has already progressed, so that the detection of the disease is delayed.
However, the cerebrospinal fluid analysis method itself is known to be a very painful to patients, and it is pointed out as a disadvantage that the risk is accompanied by the examination.
However, the method can only confirm whether or not the cranial nerve disease has developed, and a complicated pretreatment process of amyloid decomposition is required in using a nasal fluid sample.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for screening ongoing progress of alzheimer's disease by using beta amyloid oligomer in nasal discharge specimen and method for screening ongoing progress of alzheimer's disease by using same
  • Composition for screening ongoing progress of alzheimer's disease by using beta amyloid oligomer in nasal discharge specimen and method for screening ongoing progress of alzheimer's disease by using same
  • Composition for screening ongoing progress of alzheimer's disease by using beta amyloid oligomer in nasal discharge specimen and method for screening ongoing progress of alzheimer's disease by using same

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0133]Toxicity test of beta amyloid monomer and beta amyloid oligomer

[0134]1-1. Preparation of Aβ42 Oligomer

[0135]Aβ42 oligomers were prepared according to the reference (Stine WB et al. Preparing synthetic Abeta in different aggregation states. Methods Mol Biol 2011; 670: 13-32). Briefly, Aβ42 peptide (GL biochem, Shanghai) was initially dissolved in hexafluoroisopropanol at a concentration of 1 mM. For aggregation, the peptide was resuspended in dry dimethylsulfoxide at 5 mM, and then added to Hams F-12 cell culture medium (PromoCell, Labclinics, Spain) at a final concentration of 100 mM for 24 hours at 4° C. In the case of a monomer, the above polymerization process was not performed.

[0136]1-2. Cell Viability Assay

[0137]In order to confirm the toxicity of the beta amyloid monomer and the beta amyloid oligomer prepared in Example 1-1, a cell viability assay was performed using human nerve cancer cell SHSY5Y (ATCC®, CRL-2266) as follows.

[0138]Cell viability was measured using Calce...

example 2

[0139]Identification of Oligomeric Beta Amyloid Protein in Nose Discharge Sample

[0140]2-1. Subject Selection

[0141]The normal control group selected persons over the age of 60 who did not meet the other exclusion criteria and normal cognitive ability on the Seoul Neuropsychological Screening Battery (SNSB), and the patients with Alzheimer's dementia were definite Alzheimer's disease patients according to the NINCDS / ADRDA diagnosis criteria and selected persons with deterioration in two or more cognitive domains, including memory, those who have been identified as having problems with their daily life due to cognitive decline, not other causes through neuropsychological examination, and those who do not meet other exclusion criteria.

[0142]Exclusion criteria include those identified as having no brain structural problems through brain imaging (MRI or CT), people without other degenerative brain diseases, people without cerebrovascular disease that may cause cognitive impairment, people...

example 3

[0153]Quantification of Beta Amyloid Oligomers of 56 kDa and 72 kDa

[0154]As described in the reference [K.-A. Chang et al., Neurochemistry International 97 (2016)], beta amyloid oligomers of 56 kDa and 72 kDa were quantified by classifying Alzheimer's disease patient group and normal group.

[0155]Briefly, the classification criteria for normal control group include age of 65 years or older, a person having K-MMSE score of 25 or higher in the cognitive function test (KMMSE / GDS / CDR) and normal memory item (3 items-3 points) and the classification criteria for moderate Alzheimer's disease include age of 65 years or older and a person having K-MMSE of 19 points or less in the cognitive function test (KMMSE / GDS / CDR), and CDR of 1 point or higher or GDS of 3 points or higher, a person having CDR of 0.5 point and sum of box of 2.5 points or higher, a person who does not have a structural problem in the brain through brain imaging (MRI or CT) tests, a person without other degenerative brain ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a composition for screening ongoing progress of Alzheimer's disease using beta amyloid of a nose discharge sample and a method of screening ongoing progress of Alzheimer's disease using the same, more specifically, to a composition and a kit for screening ongoing progress of Alzheimer's disease, comprising an agent measuring an expression level of a 56 kDa beta amyloid oligomer and a 72 kDa beta amyloid oligomer in an nose discharge sample, and a method of screening ongoing progress of Alzheimer's disease comprising measuring the expression level of the 56 kDa and 72 kDa beta amyloid oligomers in an nose discharge sample.

Description

TECHNICAL FIELD[0001]This application claims priority of Korean Patent Application No. 10-2018-0005761 filed on Jan. 16, 2018 and is hereby incorporated herein by reference in its entirety.[0002]The present invention relates to a composition for screening ongoing progress of Alzheimer's disease using beta amyloid of a nose discharge sample and a method of screening ongoing progress of Alzheimer's disease using the same, more specifically, to a composition and a kit for screening ongoing progress of Alzheimer's disease, comprising an agent measuring an expression level of a 56 kDa beta amyloid oligomer and a 72 kDa beta amyloid oligomer in an nose discharge sample, and a method of screening ongoing progress of Alzheimer's disease comprising measuring the expression level of the 56 kDa and 72 kDa beta amyloid oligomers in an nose discharge sample. Also, the present invention relates to a method of screening a therapeutic agent for mild or moderate Alzheimer's disease comprising measur...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/68G01N33/50
CPCG01N33/6896G01N33/5088G01N2800/56G01N2333/4709G01N2800/2821G01N33/5023G01N33/53G01N2500/04
Inventor MOON, CHEILYOO, SEUNG JUNSON, GO WOONLEE, YEONG BAECHANG, KEUN A
Owner DAEGU GYEONGBUK INST OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com